source
- Arrowhead reports Phase 3 data showing potentially best-in-class triglyceride reduction, eyes FDA filingArrowhead Pharmaceuticals announced topline results from two late-stage Phase 3 trials (SHASTA-3 and SHASTA-4) of its siRNA drug plozasiran in patients with severe hypertriglyceridemia (sHTG). Th…
- Trump announces steep tariffs on imported generic drugs, starting 100% in 2028 and rising to 200% in 2029President Donald Trump disclosed a plan to levy heavy tariffs on generic medicines that are imported into the United States. The tariff would be set at 100 percent beginning in August 2028 and woul…STAT · 1mo agoRegulatoryNegative